RECCAS, REMOVE, and SIRAKI02: discrepant outcomes and a potential explanation
- PMID: 39780226
- PMCID: PMC11716001
- DOI: 10.1186/s13054-024-05236-z
RECCAS, REMOVE, and SIRAKI02: discrepant outcomes and a potential explanation
Keywords: Cardiac surgery; Endocarditis; Endotoxin; Hemoadsorption; Prolonged bypass time; Sepsis; oXiris.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Consent for publications: Not applicable. Competing interests: MMW declare to have competing interests. PMH,SB,EP & MMW declare to have no competing interests.
Comment on
-
REmoval of cytokines during CArdiac surgery (RECCAS): a randomised controlled trial.Crit Care. 2024 Dec 12;28(1):406. doi: 10.1186/s13054-024-05175-9. Crit Care. 2024. PMID: 39668341 Free PMC article. Clinical Trial.
References
-
- Diab M, Lehmann T, Bothe W, et al. REMOVE Trial Investigators*. Cytokine Hemoadsorption During Cardiac Surgery Versus Standard Surgical Care for Infective Endocarditis (REMOVE): Results From a Multicenter Randomized Controlled Trial. Circulation. 2022; 145(13):959–968. 10.1161/CIRCULATIONAHA.121.056940 - PubMed
Publication types
LinkOut - more resources
Full Text Sources
